ArticleScientific reports2026
Synthesis, docking, SAR and ADMET evaluation of novel pyrrolo[3,4-c]pyrazole-4,6-dione derivatives.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Optimization of a bis-imine scaffold as a glyoxalase I inhibitor: synthesis, SAR, and docking studies.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- DYNO-MILL-Assisted Mechanochemistry: Design of Experiments Optimization for Sustainable Synthesis of Pyrrolo[3,4-c]pyrazoles.ChemSusChem · 2026Article
- Synthesis, characterization, and DFT study of a novel pyrido[2',3':4,5]pyrimido[2,1-b][1,3]thiazines via Michael addition and intramolecular cyclization.BMC chemistry · 2026Article
- Design, Synthesis, Spectral, Structural Analysis, and Biological Evaluation of Novel Pyrazole Derivatives as Anti-Tumor, Antimicrobial, and Anti-Biofilm Agents.Antibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Novel 1,6a-dihydropyrrolo[3,4-c]pyrazole-4,6(3aH,5 H)-dione derivatives were synthesized via the reaction of hydrazonoyl bromides with N-arylmaleimides and subsequently oxidized to pyrrolo[3,4-c]pyrazole-4,6(1 H,5 H)-diones. Molecular docking against the target protein (PDB ID: 4N9S) revealed that compounds 3c and 4c exhibited the highest binding affinities (- 7.45 and - 7.31 kcal/mol, respectively), forming stable π-cation and hydrogen-bond interactions with key residues (Arg176, Glu259, Tyr257). Structure-activity relationship analysis indicated that electron-donating substituents enhanced the predicted biological activity. In silico ADMET profiling demonstrated 100% intestinal absorption, favorable distribution, and absence of toxicity, confirming the compounds' potential as promising therapeutic leads.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.